ConductScience.org, home
ES-2
API referenceFor AI assistants

Cell line · CVCL_3509

Papers80

1 to 20 of 80

Download this page as JSON
PaperJournalYearHow we knowRetractedSource
ERX-208 Induces Endoplasmic Reticulum Stress and Suppresses DNA Damage Repair to Enhance Chemotherapy Sensitivity.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion.
J Biomed Sci2026Its Methods give the RRID and name the linePubMed
Metabolic activation of LDHA by ERRα represses inflammasome-dependent pyroptosis and promotes ovarian cancer chemoresistance.Cell Death Dis2026Its Methods give the RRID and name the linePubMed
The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer.Oncogenesis2026Its Methods give the RRID and name the linePubMed
Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B.NPJ Precis Oncol2026Its Methods give the RRID and name the linePubMed
RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis.Cancer Res2026Its Methods give the RRID and name the linePubMed
BMAL2 is a druggable target for ovarian clear cell carcinoma (OCCC).EMBO Mol Med2026Its Methods give the RRID and name the linePubMed
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.Cell2026Its Methods give the RRID and name the linePubMed
Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer.Cells2026Its Methods give the RRID and name the linePubMed
Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation.Sci Adv2026Its Methods give the RRID and name the linePubMed
The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4.Cell Death Dis2026Its Methods give the RRID and name the linePubMed
Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis.J Mol Med (Berl)2026Its Methods give the RRID and name the linePubMed
PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
Targeting F2R/PAR1 with ligand decorated lipid nanocarriers for enhanced drug delivery into ovarian cancer cells.Front Drug Deliv2025Its Methods give the RRID and name the linePubMed
Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer.Signal Transduct Target Ther2025Its Methods give the RRID and name the linePubMed
Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1ß positive clear cell carcinoma.Cell Death Dis2025Its Methods give the RRID and name the linePubMed
A Tumor-homing nanoplatform for the co-delivery of triptolide and siRNA-A4B2 conspicuously overcomes peritoneum metastasis of ovarian cancer.Cell Oncol (Dordr)2025Its Methods give the RRID and name the linePubMed
3β-Hydroxysterol Δ24-Reductase Promotes Ovarian Cancer Progression by Activating the TGF-β1/Smad2/3 Signaling Pathway.Oncol Res2025Its Methods give the RRID and name the linePubMed
Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer.Cancer Res Commun2025Its Methods give the RRID and name the linePubMed
Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer.Int J Mol Sci2025Its Methods give the RRID and name the linePubMed

cell-lines-2026-11-14-0.1.0

Next page

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_3509/papers

API referenceFor AI assistants